Ensysce Biosciences (ENSC) Competitors

Ensysce Biosciences (NASDAQ:ENSC) and Chemomab Therapeutics (NASDAQ:CMMB) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, analyst recommendations, valuation, dividends and community ranking.

Does the MarketBeat Community favor ENSC or CMMB?

Chemomab Therapeutics received 16 more outperform votes than Ensysce Biosciences when rated by MarketBeat users. Likewise, 65.52% of users gave Chemomab Therapeutics an outperform vote while only 60.00% of users gave Ensysce Biosciences an outperform vote.

Company	Underperform	Outperform
Ensysce Biosciences	Outperform Votes 3 60.00%	Underperform Votes 2 40.00%
Chemomab Therapeutics	Outperform Votes 19 65.52%	Underperform Votes 10 34.48%

Which has higher earnings & valuation, ENSC or CMMB?

Ensysce Biosciences has higher revenue and earnings than Chemomab Therapeutics. Chemomab Therapeutics is trading at a lower price-to-earnings ratio than Ensysce Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ensysce Biosciences	$2.23M	2.23	-$10.61M	-$13.39	-0.23
Chemomab Therapeutics	N/A	N/A	-$24.22M	-$0.90	-1.51

Is ENSC or CMMB more profitable?

Chemomab Therapeutics has a net margin of 0.00% compared to Ensysce Biosciences' net margin of -179.26%. Chemomab Therapeutics' return on equity of -101.70% beat Ensysce Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ensysce Biosciences	-179.26%	-292.81%	-158.83%
Chemomab Therapeutics	N/A	-101.70%	-76.18%

Which has more volatility & risk, ENSC or CMMB?

Ensysce Biosciences has a beta of 1.06, meaning that its share price is 6% more volatile than the S&P 500. Comparatively, Chemomab Therapeutics has a beta of 0.66, meaning that its share price is 34% less volatile than the S&P 500.

Do analysts rate ENSC or CMMB?

Chemomab Therapeutics has a consensus price target of $9.00, suggesting a potential upside of 561.76%. Given Chemomab Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Chemomab Therapeutics is more favorable than Ensysce Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ensysce Biosciences	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Chemomab Therapeutics	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Do insiders and institutionals hold more shares of ENSC or CMMB?

5.6% of Ensysce Biosciences shares are owned by institutional investors. Comparatively, 46.0% of Chemomab Therapeutics shares are owned by institutional investors. 7.9% of Ensysce Biosciences shares are owned by insiders. Comparatively, 11.9% of Chemomab Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Does the media favor ENSC or CMMB?

In the previous week, Chemomab Therapeutics had 1 more articles in the media than Ensysce Biosciences. MarketBeat recorded 5 mentions for Chemomab Therapeutics and 4 mentions for Ensysce Biosciences. Chemomab Therapeutics' average media sentiment score of 1.04 beat Ensysce Biosciences' score of 0.30 indicating that Chemomab Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ensysce Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Chemomab Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Chemomab Therapeutics beats Ensysce Biosciences on 13 of the 17 factors compared between the two stocks.